SCHEMBL6818286

SCHEMBL6818286

CCc1ccc(CCOc2ccc(CC(C#N)CO)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.43
PPARG P37231 1/20 0.43
LMNA P02545 4/20 0.40
FFAR1 O14842 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
KMT2A Q03164 1/20 0.40
SLCO1B3 Q9NPD5 1/20 0.40
SLCO1B1 Q9Y6L6 1/20 0.40
ACACB O00763 3/20 0.39
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
PPARD Q03181 2/20 0.37
CYP2A6 P11509 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818000 0.84 PPARA (0.60) PPARAPPARGLMNAFFAR1L3MBTL1
SCHEMBL6818357 0.80 MEN1 (0.43) PPARAPPARGMEN1KMT2AACACB
SCHEMBL7620781 0.79 PPARA (0.49) PPARAPPARGLMNAFFAR1L3MBTL1
SCHEMBL6817504 0.77 PPARG (0.44) PPARAPPARGLMNAFFAR1L3MBTL1
SCHEMBL6818157 0.77 PPARA (0.52) PPARAPPARGLMNAFFAR1L3MBTL1
SCHEMBL6813832 0.73 PPARA (0.48) PPARAPPARGLMNAFFAR1L3MBTL1
SCHEMBL6813813 0.72 PPARA (0.76) PPARAPPARGPPARD
SCHEMBL301362 0.72 NR1I2 (0.60) LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1
SCHEMBL8275557 0.71 NPC1 (0.65) PPARGLMNAFFAR1L3MBTL1MEN1
SCHEMBL5501854 0.71 TRPA1 (0.52) LMNAFFAR1ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237857-B1 NEW PHENALKYLOXY-PHENYL DERIVATIVES ASTRAZENECA AB (SE) 2004-06-30 EP disclosed
US-6630509-B2 Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin ASTRAZENECA AB (SE) 2003-10-07 US disclosed
US-20030018207-A1 Phenalkyloxy-phenyl derivatives ASTRAZENECA AB (SE) 2003-01-23 US disclosed
EP-1237857-A1 NEW PHENALKYLOXY-PHENYL DERIVATIVES AstraZeneca AB (SE) 2002-09-11 EP disclosed
WO-2001040170-A1 NEW PHENALKYLOXY-PHENYL DERIVATIVES ASTRAZENECA AB (SE) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018207-A1 Phenalkyloxy-phenyl derivatives GPR119, INSR, IAPP PPARA 74/4885PPARG 47/4885LMNA 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.